Telix Pharmaceuticals (TLX) H1 2024 earnings summary

Executive summary

• Achieved 65% year-over-year revenue growth to $364.0M in H1 2024, driven by IlluccixⓇ/Illuccix® U.S. sales and global expansion across prostate, kidney, and brain cancer programs.

• Net profit after tax was $29.7M, a turnaround from a $14.3M loss in H1 2023.

• Completed strategic acquisitions of ARTMS, IsoTherapeutics, and QSAM Biosciences, enhancing manufacturing, supply chain, and product pipeline.

• Raised $650M (AUD 650M) in convertible bonds post-period, strengthening the balance sheet for accelerated clinical development and strategic growth.

• Gross margin improved to 66% from 63% in H1 2023, reflecting stable pricing and cost control.

Financial highlights

• Revenue from contracts with customers reached $363.96M, up from $220.83M in H1 2023.

• Adjusted EBITDA increased 66% to $57.5M (H1 2023: $34.7M).

• Adjusted EBITDAR grew to $137.1M, up 69% from $81.3M in H1 2023.

• Operating profit from the commercial business rose 86% to AUD 175 million, representing 49% of sales.

• Operating cash inflow rose to $39.1M (H1 2023: $13.3M); cash balance at 30 June 2024 was $118.8M.

Outlook and guidance

• Full-year revenue guidance set at US$490M–US$510M (A$745M–A$776M), a 48–54% increase on 2023.

• R&D expenditure for 2024 expected to increase 40–50% over 2023, with 23% of revenue allocated to pipeline development.

• Focused on advancing pivotal trials for prostate, kidney, and brain cancer therapies, with regulatory approvals and launches for new diagnostics expected in the U.S., EU, UK, and Brazil.

• International expansion, especially in Europe, APAC, and Latin America, remains a priority.

• Convertible bond proceeds to fund label expansion, pivotal trials, and potential M&A.